Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Expenses: 2016-2025

Historic Operating Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $132.3 million.

  • Tg Therapeutics' Operating Expenses rose 85.24% to $132.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 61.75%. This contributed to the annual value of $287.1 million for FY2024, which is 34.76% up from last year.
  • As of Q3 2025, Tg Therapeutics' Operating Expenses stood at $132.3 million, which was up 24.49% from $106.3 million recorded in Q2 2025.
  • Tg Therapeutics' Operating Expenses' 5-year high stood at $132.3 million during Q3 2025, with a 5-year trough of $35.1 million in Q3 2022.
  • Moreover, its 3-year median value for Operating Expenses was $71.4 million (2024), whereas its average is $77.4 million.
  • As far as peak fluctuations go, Tg Therapeutics' Operating Expenses tumbled by 59.78% in 2022, and later spiked by 85.24% in 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Expenses (Quarterly) stood at $95.3 million in 2021, then decreased by 18.53% to $77.6 million in 2022, then dropped by 27.27% to $56.5 million in 2023, then soared by 38.58% to $78.2 million in 2024, then surged by 85.24% to $132.3 million in 2025.
  • Its Operating Expenses was $132.3 million in Q3 2025, compared to $106.3 million in Q2 2025 and $112.2 million in Q1 2025.